RULES WERE NOT MEANT FOR THIS BMW. There's a reason the 2 Series is so loved. Blisteringly fast, the 335-horsepower rear-wheel drive M240i Coupe sprints from 0 to 60 mph in just 4.4 seconds, or 4.2 seconds with xDrive, and handles with a steering agility and control that are incredibly precise.
FDA Approves Tecentriq Immunotherapy for Specific Type of Advanced Lung Cancer. The U.S. Food and Drug Administration (FDA) approved Genentechâs Tecentriq (atezolizumab) as a treatment for people with metastatic non-small cell lung cancer (NSCLC).
Download resources for TECENTRIQÂ® (atezolizumab) non-small cell lung cancer (NSCLC) treatment.. TECENTRIQ INDICATION Metastatic Non-Small Cell Lung Cancer (NSCLC). TECENTRIQ is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ.